PURE Bioscience Overview
Latest ROE for PURE Bioscience: 37.76% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow37.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for PURE is 37.76%. That is above the sector sector average of -6.13%. Investors often review this figure alongside PURE Bioscience's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, PURE currently prints 37.76% for ROE, while the sector average sits near -6.13%. That is roughly 716.2% above the sector mean. Large gaps often invite a closer look at PURE Bioscience's growth, margins, and balance sheet.
Return on Equity shows how effectively PURE Bioscience converts resources into returns. At 37.76%, PURE may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting PURE's ROE (37.76%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
